Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Perspective Therapeutics (CATX) is set to announce its quarterly earnings on Wednesday, August 13th, with anticipated losses of ($0.30) per share and revenue of $0.17 million.
• The stock currently has a consensus rating of "Buy", with an average price target of $12.56 according to multiple analysts' ratings.
• Perspective Therapeutics is developing precision-targeted alpha therapies for oncology, with candidates VMT-a-NET and VMT01 currently in Phase 1/2a clinical trials.

Perspective Therapeutics (NYSE:CATX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $0.17 million for the quarter.

Perspective Therapeutics Price Performance

CATX stock traded up $0.05 during trading on Friday, hitting $3.68. 371,049 shares of the company's stock traded hands, compared to its average volume of 952,907. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.55. The business has a fifty day simple moving average of $3.68 and a 200 day simple moving average of $2.96.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CATX. B. Riley reissued a "buy" rating and issued a $12.00 target price (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Truist Financial cut their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their target price for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Finally, Wedbush restated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Monday, June 23rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $12.56.

Institutional Trading of Perspective Therapeutics

An institutional investor recently raised its position in Perspective Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 15.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,382,814 shares of the company's stock after acquiring an additional 188,887 shares during the period. Geode Capital Management LLC owned approximately 1.86% of Perspective Therapeutics worth $4,758,000 at the end of the most recent quarter. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.